Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 1/20 | 0.38 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | ABHD16A | O95870 | 1/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.34 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.34 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.34 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | KDM5A | P29375 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15638493 | 0.81 | ALDH1A1 (0.41) | NR3C2FLT3MEN1KMT2ANOTUM | |
| SCHEMBL15638654 | 0.81 | MEN1 (0.43) | OXTRNR3C2FLT3MEN1KMT2A | |
| SCHEMBL519029 | 0.81 | POLB (0.52) | NR3C2KDM4E | |
| SCHEMBL15638806 | 0.81 | MGLL (0.44) | OXTRNOTUMORAI1ORAI2ORAI3 | |
| SCHEMBL19142889 | 0.80 | OXTR (0.34) | OXTRNR3C2FLT3KDM4EMEN1 | |
| SCHEMBL596438 | 0.77 | ENPP2 (0.44) | KDM4ENOTUMMAPK14KDM5AKDM2B | |
| SCHEMBL14696217 | 0.75 | KDM4E (0.42) | OXTRNR3C2FLT3KDM4EMEN1 | |
| SCHEMBL19143226 | 0.71 | ALDH1A1 (0.39) | NR3C2FLT3KMT2ANOTUMNPBWR1 | |
| SCHEMBL15779574 | 0.71 | OXTR (0.48) | OXTRNR3C2FLT3KDM4EMEN1 | |
| SCHEMBL15553415 | 0.71 | OXTR (0.41) | OXTRNR3C2FLT3KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2903980-B1 | BENZIMIDAZOLES AS CNS ACTIVE AGENTS | HOFFMANN LA ROCHE (CH) | 2017-07-19 | — | — | EP | disclosed |
| EP-2903980-B1 | BENZIMIDAZOLES AS CNS ACTIVE AGENTS | HOFFMANN LA ROCHE (CH) | 2017-07-19 | — | — | EP | disclosed |
| CN-104703981-B | As the benzimidazoles compound of CNS activity medicament | 霍夫曼-拉罗奇有限公司 | 2017-03-29 | — | — | CN | disclosed |
| US-9365550-B2 | Benzimidazoles as CNS active agents | HOFFMANN-LA ROCHE INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-9365550-B2 | Benzimidazoles as CNS active agents | HOFFMANN-LA ROCHE INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-9365550-B2 | Benzimidazoles as CNS active agents | HOFFMANN-LA ROCHE INC. (US) | 2016-06-14 | — | — | US | disclosed |
| EP-2903980-A1 | BENZIMIDAZOLES AS CNS ACTIVE AGENTS | F. Hoffmann-La Roche AG (CH) | 2015-08-12 | — | — | EP | disclosed |
| US-20150203472-A1 | BENZIMIDAZOLES AS CNS ACTIVE AGENTS | HOFFMANN-LA ROCHE INC. (US) | 2015-07-23 | — | — | US | disclosed |
| US-20150203472-A1 | BENZIMIDAZOLES AS CNS ACTIVE AGENTS | HOFFMANN-LA ROCHE INC. (US) | 2015-07-23 | — | — | US | disclosed |
| US-20150203472-A1 | BENZIMIDAZOLES AS CNS ACTIVE AGENTS | HOFFMANN-LA ROCHE INC. (US) | 2015-07-23 | — | — | US | disclosed |
| CN-104703981-A | Benzimidazol.es as CNS active agents | HOFFMANN LA ROCHE | 2015-06-10 | — | — | CN | disclosed |
| WO-2014053409-A1 | BENZIMIDAZOL.ES AS CNS ACTIVE AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203472-A1 | BENZIMIDAZOLES AS CNS ACTIVE AGENTS | CDR2, HTR2B, HCRTR1 | OXTR 342/4885NR3C2 128/4885FLT3 2508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.